Related Experiment Videos
PTEN/MMAC1 mutations in endometrial cancers
J I Risinger1, A K Hayes, A Berchuck
1Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA.
Cancer Research
|November 14, 1997
Summary
Mutations in the PTEN/MMAC1 gene were found in 34% of endometrial carcinomas, indicating its significant role in gynecological cancer development. This discovery highlights PTEN/MMAC1 as a frequently altered gene in endometrial tumors.
Area of Science:
- Oncology
- Molecular Genetics
- Gynecology
Background:
- Endometrial carcinoma is the most common gynecological cancer in the US.
- Chromosome 10 alterations, including loss of heterozygosity (LOH), are implicated in endometrial cancer pathogenesis.
- PTEN/MMAC1, a tumor suppressor gene on chromosome 10, is mutated in various advanced cancers and familial cancer syndromes.
Purpose of the Study:
- To investigate the frequency and spectrum of PTEN/MMAC1 alterations in endometrial carcinomas.
- To determine if PTEN/MMAC1 mutations are a common event in endometrial cancer development.
Main Methods:
- Analysis of PTEN/MMAC1 gene alterations in 70 endometrial carcinoma samples.
- Detection of somatic mutations, including truncations, missense alterations, and insertions.
Main Results:
- Somatic mutations in PTEN/MMAC1 were detected in 24 out of 70 (34%) endometrial carcinomas.
- Mutations included premature protein truncation (21 cases), alterations in the phosphatase domain (2 cases), and a large insertion (1 case).
- PTEN/MMAC1 mutations occurred more frequently than any other known gene alterations in endometrial cancers.
Conclusions:
- PTEN/MMAC1 is a frequently mutated gene in endometrial carcinoma.
- Alterations in PTEN/MMAC1 are significant contributors to the molecular pathogenesis of endometrial cancer.
- These findings identify PTEN/MMAC1 as a key player in gynecological tumorigenesis.